Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jessica Taaffe & David Wilson. (2018) Mobilising a global response to hepatitis: Lessons learned from the HIV movement. Global Public Health 13:4, pages 473-488.
Read now
Read now
Articles from other publishers (49)
Layal Al Mahmasani, Umayya Musharrafieh, Zeina Bayram & Abdul Rahman Bizri. (2023) Hepatitis B and C: neglected infectious diseases among Syrian refugees in Lebanon. Journal of Global Health Reports 7.
Crossref
Crossref
Young Mi Hong, Ki Tae Yoon, Young Joo Park, Hyun Young Woo & Jeong Heo. (2023) Seroprevalence of Hepatitis C Virus Infection in North Korean Defectors Residing in Korea. Journal of Korean Medical Science 38:34.
Crossref
Crossref
Ragunath Barath, Kaviarasan Vaishak & Ramakrishnan Veerabathiran. 2023. Oncogenic Viruses. Oncogenic Viruses
145
170
.
Tomislav PREVEDEN, Benjamin VERES, Maja RUZIC, Maria PETE, Sanja BOGIC, Nadica KOVACEVIC, Anna C. PROCOPIO, Sharmila FAGOONE, Francesco LUZZA & Ludovico ABENAVOLI. (2022) Triglyceride-glucose index and hepatic steatosis index for the assessment of liver steatosis in HCV patients. Minerva Gastroenterology.
Crossref
Crossref
Dante Romagnoli. (2022) Elimination of hepatitis C virus infection in Europe: targeting the obstacles. Exploration of Medicine, pages 71-76.
Crossref
Crossref
R. A. Yakhina, I. A. Lakman, D. A. Valishin & R. Kh. Bakhitova. (2022) Economic burden of chronic viral hepatitis C. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14:4, pages 523-536.
Crossref
Crossref
Ching Chang, Chien-Hao Huang, Hsiao-Jung Tseng, Fang-Chen Yang & Rong-Nan Chien. (2021) Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan. Journal of Personalized Medicine 11:6, pages 478.
Crossref
Crossref
Anna Citarella, Simona Cammarota, Francesca F. Bernardi, Carmine Coppola, Maria D’Antò, Marianna Fogliasecca, Elio Giusto, Mario Masarone, Angelo Salomone Megna, Carmine Sellitto, Rosa Servodio, Massimo Smaldone, Laura Staiano, Ugo Trama, Valeria Conti & Marcello Persico. (2020) Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. Life 10:12, pages 359.
Crossref
Crossref
T. Joseph MattinglyIIII, Bryan L. Love & Bilal Khokhar. (2020) Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. PharmacoEconomics 38:9, pages 927-939.
Crossref
Crossref
Camila Guerra Marangon, Jóice Teixeira de Bitencorte, Rafael Tomoya Michita, Vagner Ricardo Lunge, Deivid Cruz dos Santos, Mário Reis Álvares-da-Silva & Daniel Simon. (2019) Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients. Pathology & Oncology Research 26:3, pages 1519-1525.
Crossref
Crossref
Adugna Endale Woldegiorgis, Woldearegay Erku, Girmay Medhin, Nega Berhe & Mengistu Legesse. (2019) Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia. PLOS ONE 14:12, pages e0226890.
Crossref
Crossref
Masoud Behzadifar, Hasan Abolghasem Gorji, Aziz Rezapour, Meysam Behzadifar & Nicola Luigi Bragazzi. (2019) The role of insurance providers in supporting treatment and management of hepatitis C patients. BMC Health Services Research 19:1.
Crossref
Crossref
Simona Cammarota, Anna Citarella, Antonella Guida, Valeria Conti, Teresa Iannaccone, Maria Elena Flacco, Francesca Bravi, Cristina Naccarato, Antonella Piscitelli, Raffaele Piscitelli, Alfredo Valente, Giulio Calella, Nicola Coppola & Giustino Parruti. (2019) The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study). PLOS ONE 14:7, pages e0219396.
Crossref
Crossref
Maria Kalafateli, Elena Buzzetti, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis & Kurinchi Selvan Gurusamy. (2018) Pharmacological interventions for acute hepatitis C infection. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Meryem Jefferies, Bisma Rauff, Harunor Rashid, Thao Lam & Shafquat Rafiq. (2018) Update on global epidemiology of viral hepatitis and preventive strategies. World Journal of Clinical Cases 6:13, pages 589-599.
Crossref
Crossref
Christina Greenaway, Iuliia Makarenko, Claire Abou Chakra, Balqis Alabdulkarim, Robin Christensen, Adam Palayew, Anh Tran, Lukas Staub, Manish Pareek, Joerg Meerpohl, Teymur Noori, Irene Veldhuijzen, Kevin Pottie, Francesco Castelli & Rachael Morton. (2018) The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. International Journal of Environmental Research and Public Health 15:9, pages 2013.
Crossref
Crossref
P. Cacoub, P. Buggisch, J. A. Carrión, G. S. Cooke, A. L. Zignego, R. Beckerman & Z. Younossi. (2018) Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. Journal of Viral Hepatitis 25:7, pages 811-817.
Crossref
Crossref
Guy Neff & Woodie Zachry III. (2018) Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. PharmacoEconomics 36:7, pages 809-822.
Crossref
Crossref
Maria Stepanova, Issah Younossi, Andrei Racila & Zobair M. Younossi. (2018) Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). Value in Health 21:5, pages 612-621.
Crossref
Crossref
D. Salmon, M. U. Mondelli, M. Maticic & J. E. Arends. (2018) The benefits of hepatitis C virus cure: Every rose has thorns. Journal of Viral Hepatitis 25:4, pages 320-328.
Crossref
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbilidad, medicación concomitante, uso de recursos y costes sanitarios asociados a los pacientes portadores del virus de la hepatitis C crónica en España. Gastroenterología y Hepatología 41:4, pages 234-244.
Crossref
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterología y Hepatología (English Edition) 41:4, pages 234-244.
Crossref
Crossref
Shahinul Alam, Shah Mohammad Fahim, Muhammad Abdul Baker Chowdhury, Md. Zakiul Hassan, Golam Azam, Golam Mustafa, Mainul Ahsan & Nooruddin Ahmad. (2018) Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open 2:2, pages 39-46.
Crossref
Crossref
Z. M. Younossi, H. L. Y. Chan, Y. Y. Dan, M. H. Lee, Y. -S. Lim, E. Kruger & S. C. Tan. (2018) Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. Journal of Viral Hepatitis 25:3, pages 228-235.
Crossref
Crossref
Evangelista Sagnelli, Loredana Alessio, Caterina Sagnelli, Luciano Gualdieri, Mariantonietta Pisaturo, Carmine Minichini, Giovanni Di Caprio, Mario Starace, Lorenzo Onorato, Gaetano Scotto, Margherita Macera & Nicola Coppola. (2018) Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. Annals of Hepatology 17:1, pages 47-53.
Crossref
Crossref
Christina Greenaway, Laurent Azoulay, Robert Allard, Joseph Cox, Viet Anh Tran, Claire Nour Abou Chakra, Russ Steele & Marina Klein. (2017) A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infectious Diseases 17:1.
Crossref
Crossref
Do Young Kim. (2017) Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy. Gut and Liver 11:6, pages 745-746.
Crossref
Crossref
Necati Örmeci, Simten Malhan, İsmail Balık, Gül Ergör, Homie Razavi & Sarah Robbins. (2017) Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatology International 11:6, pages 509-516.
Crossref
Crossref
Aijaz Ahmed, Stevan A. Gonzalez, George Cholankeril, Ryan B. Perumpail, Justin McGinnis, Sammy Saab, Rachel Beckerman & Zobair M. Younossi. (2017) Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States. Hepatology 66:1, pages 46-56.
Crossref
Crossref
Jean Joel Bigna, Marie A Amougou, Serra Lem Asangbeh, Angeladine Malaha Kenne, Steve Raoul N Noumegni, Elodie T Ngo-Malabo & Jean Jacques Noubiap. (2017) Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open 7:6, pages e015298.
Crossref
Crossref
Maria Kalafateli, Elena Buzzetti, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis & Kurinchi Selvan Gurusamy. (2017) Pharmacological interventions for acute hepatitis C infection. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Nattiya Kapol, Surasit Lochid-amnuay & Yot Teerawattananon. (2016) Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterology 16:1.
Crossref
Crossref
Florian Bert, Andreas Rindermann, Murad A. Abdelfattah, Jona T. Stahmeyer & Siegbert Rossol. (2016) High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. European Journal of Gastroenterology & Hepatology 28:11, pages 1246-1252.
Crossref
Crossref
Zobair M. Younossi, Aybike Birerdinc & Linda Henry. (2016) Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 65:1, pages S109-S119.
Crossref
Crossref
Do Young Kim, Ki Tae Yoon, Won Kim, Jung Il Lee, Sung Hwi Hong, Danbi Lee, Jeong Won Jang, Jong Won Choi, Ilsu Kim & Yong Han Paik. (2016) Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine 95:30, pages e3896.
Crossref
Crossref
Jayne Smith-Palmer, Karin Cerri & William Valentine. (2015) Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases 15:1.
Crossref
Crossref
Prarthana Thiagarajan & Stephen D. Ryder. (2015) The hepatitis C revolution part 1. Current Opinion in Infectious Diseases 28:6, pages 563-571.
Crossref
Crossref
Christina Greenaway, Ann Thu Ma, Lorie A. Kloda, Marina Klein, Sonya Cnossen, Guido Schwarzer & Ian Shrier. (2015) The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLOS ONE 10:11, pages e0141715.
Crossref
Crossref
Juliet Bell. (2015) Conquering C – Going Beyond Cure. EMJ Hepatology, pages 42-51.
Crossref
Crossref
Jennifer C. Samp, Richard Perry, James Piercy, Robert Wood & Robert W. Baran. (2015) Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clinics and Research in Hepatology and Gastroenterology 39:3, pages 307-314.
Crossref
Crossref
Kurinchi Selvan Gurusamy, Douglas Thorburn, Emmanuel Tsochatzis & Brian R Davidson. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Kurinchi Selvan Gurusamy, Clare D Toon, Douglas Thorburn, Emmanuel Tsochatzis & Brian R Davidson. (2015) Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Fasiha Kanwal & Michael L. Volk. 2015. Complications of Cirrhosis. Complications of Cirrhosis
309
315
.
Matthew E Cramp, William M Rosenberg, Steven D Ryder, Sarah Blach & Julie Parkes. (2014) Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterology 14:1.
Crossref
Crossref
Aikaterini Vellopoulou, Michel van Agthoven, Annemarie van der Kolk, Robert J. de Knegt, Gilles Berdeaux, Sandrine Cure, Florence Bianic & Mark Lamotte. (2014) Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Applied Health Economics and Health Policy 12:6, pages 647-659.
Crossref
Crossref
Naveed Z. Janjua, Bushra Mahmood & M. Imran Khan. (2014) Does knowledge about bloodborne pathogens influence the reuse of medical injection syringes among women in Pakistan?. Journal of Infection and Public Health 7:4, pages 345-355.
Crossref
Crossref
Michel Rotily, Alexandre Vainchtock, Baptiste Jouaneton, Claire Wartelle-Bladou & Armand Abergel. (2013) How did chronic hepatitis C impact costs related to hospital health care in France in 2009?. Clinics and Research in Hepatology and Gastroenterology 37:4, pages 365-372.
Crossref
Crossref
Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury & Elamin Elbasha. (2013) Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. Journal of Health Economics and Outcomes Research 1:1, pages 62-82.
Crossref
Crossref
Marcus Paulo da Silva Rodrigues, Cid Manso de Mello Vianna, Gabriela Bittencourt Gonzalez Mosegui, Frances Valéria Costa e Silva, Antonio Augusto de Freitas Peregrino & Fernando Nagib Jardim. (2013) Custo-efetividade da inclusão dos respondedores virológicos lentos no tratamento da hepatite C na presença da coinfecção com o HIV. Cadernos de Saúde Pública 29:suppl 1, pages s146-s158.
Crossref
Crossref